The earnings call reflects a strategic focus on transitioning to a pure-play Patient Direct business with positive growth in certain categories and effective working capital management. However, challenges such as costs related to the Rotech acquisition, diabetes segment disruptions, and potential increases in stranded costs present hurdles.

Company Guidance -

Q3 2025

During the Owens & Minor second quarter 2025 earnings call, the company provided guidance for the remainder of the year, emphasizing its focus on the Patient Direct business following the planned divestiture of the Products & Healthcare Services segment. For 2025, Owens & Minor expects Patient Direct revenue to range between $2.76 billion and $2.82 billion, with an adjusted EBITDA between $376 million and $382 million. The company highlighted a projected adjusted net income per share of $1.02 to $1.07 for the year. Key growth drivers include the Sleep Journey program and strong performance in sleep, ostomy, and urology categories, while diabetes faced headwinds due to supplier disruptions. The company also plans to mitigate stranded costs, which amounted to $11 million in Q2 2025, and focus on debt reduction using proceeds from the divestiture. Adjusted EBITDA margin for the second quarter was 14.2%, and the company anticipates a similar margin trajectory, contingent on the divestiture's timeline.

Focus on Patient Direct Business

Owens & Minor is transitioning to a pure-play Patient Direct business, focusing on home-based care with projected revenue of $2.76 billion to $2.82 billion and adjusted EBITDA of $376 million to $382 million for 2025.

Revenue and EBITDA Growth

Revenue for the quarter was $682 million, a 3.3% increase from the previous year, and adjusted EBITDA rose to $96.6 million from $91.1 million, driven by volume growth, improved collection rates, and productivity gains.

Strong Performance in Sleep and Other Categories

Strong growth in sleep supplies, ostomy, and urology categories, with double-digit growth in some segments.

Successful Working Capital Management

Significant working capital reduction of nearly $94 million was achieved in the quarter, driven by lower inventory levels and improved collection rates.

Owens & Minor (OMI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

OMI Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	0.28 / -	0.42	―	―	―
Aug 11, 2025	2025 (Q2)	0.28 / 0.26	0.36	-27.78% (-0.10)
May 08, 2025	2025 (Q1)	0.20 / 0.23	0.19	21.05% (+0.04)
Feb 28, 2025	2024 (Q4)	0.52 / 0.55	0.69	-20.29% (-0.14)
Nov 04, 2024	2024 (Q3)	0.41 / 0.42	0.44	-4.55% (-0.02)
Aug 02, 2024	2024 (Q2)	0.33 / 0.36	0.18	100.00% (+0.18)
May 03, 2024	2024 (Q1)	0.18 / 0.19	0.05	280.00% (+0.14)
Feb 20, 2024	2023 (Q4)	0.66 / 0.69	0.28	146.43% (+0.41)
Nov 03, 2023	2023 (Q3)	0.38 / 0.44	0.41	7.32% (+0.03)
Aug 04, 2023	2023 (Q2)	0.18 / 0.18	0.76	-76.32% (-0.58)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

OMI Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 11, 2025	$7.09	$4.63	-34.70%
May 08, 2025	$7.76	$6.99	-9.92%
Feb 28, 2025	$6.89	$9.58	+39.04%
Nov 04, 2024	$13.36	$12.00	-10.18%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.